Summary
Global Monkeypox Therapeutics Market was valued at USD 85.26 Million in 2023 and is expected to reach USD 116.38 Million by 2029 with a CAGR of 8.82% during the forecast period. The resurgence of Monkeypox cases, particularly in non-endemic regions, has heightened the demand for targeted therapeutic interventions. The global increase in outbreaks is attributed to factors such as deforestation, climate change, and the international trade of exotic animals, which have increased human exposure to the virus. In response, governments and healthcare organizations are investing heavily in research and development (R&D) to accelerate the discovery of novel treatments and vaccines.
One of the primary drivers of the Monkeypox therapeutics market is the rising awareness of the disease and the subsequent demand for effective treatment solutions. Governments worldwide are prioritizing public health initiatives aimed at controlling the spread of Monkeypox, which includes stockpiling antiviral drugs and vaccines. This proactive approach is fueling the demand for therapeutics, thereby driving market growth.
Despite the promising outlook, the Monkeypox therapeutics market faces several challenges. The limited availability of approved drugs and vaccines poses a significant hurdle, as does the logistical challenge of distributing these treatments to remote and underserved areas. Moreover, the high cost of R&D and the lengthy approval process for new drugs can hinder the timely introduction of innovative therapies.
However, these challenges also present opportunities for market players. The increasing focus on global health security and pandemic preparedness is likely to drive investments in Monkeypox therapeutics. Companies that can navigate the regulatory landscape and bring effective treatments to market swiftly will be well-positioned to capitalize on the growing demand. Additionally, the development of combination therapies, which offer more comprehensive treatment options, is an area ripe for innovation and could lead to significant market expansion.
Key Market Drivers
Growing Prevalence of Monkeypox
The recent surge in Monkeypox cases globally can be attributed to several factors, including increased human-animal interactions, urbanization, and climate change. As the disease transcends its traditional geographic boundaries, there has been a marked rise in the number of reported cases in Europe, North America, and Asia. This unprecedented spread has intensified the need for targeted therapeutics, significantly impacting the dynamics of the global Monkeypox therapeutics market.
According to a 2023 report by the World Health Organization, a sudden outbreak of Mpox emerged in May 2022, rapidly spreading across Europe, the Americas, and all six WHO regions. By the end of the outbreak, 110 countries had reported approximately 87,000 cases and 112 deaths. The outbreak predominantly affected, though was not limited to, gay, bisexual, and other men who have sex with men, with transmission occurring primarily through sexual networks. Additionally, in 2022, Mpox outbreaks caused by Clade I MPXV were observed in refugee camps in the Republic of Sudan. No zoonotic origin has been identified.
The heightened prevalence of Monkeypox has prompted a swift response from the pharmaceutical industry, with companies focusing on the development and distribution of antiviral drugs, vaccines, and supportive care treatments. The market is witnessing increased investment in research and development (R&D) aimed at repurposing existing antiviral medications, such as Tecovirimat, and creating novel therapies tailored specifically for Monkeypox. The urgency to address the growing number of cases has accelerated the regulatory approval process in many regions, facilitating the rapid deployment of treatments to affected populations.
Governments worldwide are playing a pivotal role in driving the growth of the Monkeypox therapeutics market. The rising prevalence of the disease has led to a heightened focus on public health preparedness, with many governments initiating stockpiling strategies for antiviral drugs and vaccines. In addition, international organizations such as the World Health Organization (WHO) are actively collaborating with national health agencies to monitor and control the spread of Monkeypox. These coordinated efforts are creating a conducive environment for market growth, as they ensure that therapeutic solutions reach the populations most in need.
Surge in Regulatory Approvals of Monkeypox Therapeutics
The unexpected proliferation of monkeypox, particularly in non-endemic regions, has created an urgent need for effective medical interventions. In response, regulatory bodies worldwide have taken decisive action to fast-track the approval of therapeutics. This accelerated regulatory environment is a reflection of both the pressing public health need and the lessons learned from the COVID-19 pandemic, where rapid approval processes proved crucial in mitigating the spread of the virus.
According to a 2024 report by the World Health Organization, WHO has issued a call for manufacturers of Mpox vaccines to submit an Expression of Interest for Emergency Use Listing (EUL). The EUL process is designed to expedite the approval of unlicensed medical products, such as vaccines, during public health emergencies. This time-limited recommendation is based on a risk-benefit assessment. WHO is requesting manufacturers to provide data demonstrating that the vaccines are safe, effective, of high quality, and appropriate for the intended populations.
Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have been at the forefront, expediting the review and approval processes for monkeypox therapeutics. These agencies have recognized the need to balance thorough evaluation with speed, ensuring that effective treatments are made available without unnecessary delays. This regulatory agility has been instrumental in addressing the immediate healthcare demands posed by the outbreak.
The surge in regulatory approvals is significantly impacting the global Monkeypox Therapeutics Market by enhancing the availability and accessibility of treatments. As more therapeutics receive the green light from regulatory bodies, pharmaceutical companies are able to scale up production and distribution efforts, ensuring that treatments reach affected populations swiftly. This not only helps in curbing the spread of the disease but also stimulates market growth by creating a robust supply chain.
Moreover, the expedited approval of therapeutics has encouraged pharmaceutical innovation. Companies are now more inclined to invest in the research and development of new treatments, knowing that the regulatory pathway has been streamlined. This has led to a proliferation of new products entering the market, further driving its expansion.
The surge in regulatory approvals has also fostered global collaboration, with governments, pharmaceutical companies, and international health organizations working together to address the monkeypox threat. Strategic partnerships have been formed to facilitate the rapid development, approval, and distribution of therapeutics. These collaborations are vital in ensuring that treatments are not only approved quickly but also reach a global audience, particularly in low- and middle-income countries where healthcare infrastructure may be less developed.
In addition, the harmonization of regulatory standards across different regions has been a key enabler of this global effort. By aligning their approval processes, regulatory bodies are making it easier for pharmaceutical companies to navigate the complex landscape of international regulations, thereby accelerating the global distribution of approved therapeutics.
Key Market Challenges
Disruptions in Supply Chain
As the global political landscape becomes increasingly volatile, the risk of trade restrictions, sanctions, and other barriers to international commerce rises. These factors can delay the production and distribution of pharmaceuticals by limiting access to critical raw materials, increasing transportation costs, and complicating cross-border transactions. For instance, countries involved in producing the active pharmaceutical ingredients (APIs) essential for Monkeypox treatments may face export restrictions or sanctions, leading to shortages and price hikes that affect the entire supply chain.
The COVID-19 pandemic has profoundly impacted global supply chains, and its effects continue to reverberate across various sectors, including the pharmaceutical industry. The pandemic exposed the vulnerabilities of just-in-time inventory systems and the overreliance on a limited number of suppliers, particularly in Asia. Factory shutdowns, workforce reductions, and transportation bottlenecks during the pandemic created a ripple effect that disrupted the production and distribution of many essential medicines, including those for Monkeypox. Although the world has started to recover, these challenges persist, with supply chains remaining fragile and susceptible to future disruptions.
The production of Monkeypox therapeutics relies on a steady supply of high-quality raw materials, many of which are sourced from a small number of global suppliers. Any disruption in the supply of these materials can lead to significant delays in manufacturing, affecting the availability of therapeutics during critical periods. For example, shortages of specific chemicals or biological materials required for vaccine production can halt entire production lines, leading to gaps in the supply chain that are difficult to bridge quickly. Furthermore, manufacturing bottlenecks can occur if demand for these therapeutics suddenly spikes during an outbreak, overwhelming production capacity and leading to further delays.
Even when therapeutics are produced on time, getting them to the right place at the right time remains a significant challenge. The global distribution of pharmaceuticals is a complex process that involves multiple stakeholders, including manufacturers, logistics providers, regulatory agencies, and healthcare facilities. Transportation delays, whether due to regulatory hurdles, natural disasters, or infrastructure limitations, can lead to critical shortages in regions where Monkeypox outbreaks are most severe. In low- and middle-income countries, where infrastructure may already be inadequate, these logistical challenges are even more pronounced, exacerbating the difficulties in managing and treating Monkeypox.
Key Market Trends
Growing Focus on Vulnerable Populations
The global monkeypox therapeutics market is undergoing significant transformation as the world grapples with the ongoing threat of monkeypox outbreaks. A notable trend shaping this market is the increasing focus on vulnerable populations. These populations, which include immunocompromised individuals, children, the elderly, and people with pre-existing health conditions, are at heightened risk of severe outcomes if infected with the monkeypox virus. As a result, pharmaceutical companies, healthcare providers, and policymakers are prioritizing the development of targeted therapeutics and intervention strategies to protect these at-risk groups.
Immunocompromised individuals, such as those with HIV/AIDS, cancer patients undergoing chemotherapy, and organ transplant recipients, represent a particularly vulnerable segment of the population. Their weakened immune systems make them more susceptible to infections and less responsive to standard treatments. This reality has driven the need for specialized therapeutics tailored to their unique requirements. Pharmaceutical companies are increasingly investing in research and development (R&D) to create antiviral therapies that are not only effective but also safe for use in these sensitive patient groups. Additionally, dose adjustments and alternative drug formulations are being explored to enhance the efficacy and reduce the potential for adverse reactions in immunocompromised patients. These efforts are critical in ensuring that life-saving treatments are accessible to those who need them most.
Children and the elderly are also at greater risk of severe disease outcomes due to their relatively weaker immune systems. The pediatric population, in particular, requires age-appropriate formulations of monkeypox therapeutics. This has led to the development of pediatric-specific vaccines and antiviral drugs that account for factors such as body weight, developmental stage, and the potential for different side effects in younger patients. Similarly, the geriatric population requires careful consideration due to the presence of comorbidities and the increased likelihood of drug interactions. Pharmaceutical companies are therefore focusing on creating therapeutics that are effective for older adults while minimizing the risk of complications.
To ensure the safety and efficacy of monkeypox therapeutics across diverse populations, there is a growing emphasis on inclusive clinical trials. Historically, clinical trials have often excluded vulnerable populations, leading to a lack of data on how these groups respond to new treatments. However, this trend is changing as regulatory bodies and industry stakeholders recognize the importance of including a broad demographic spectrum in clinical research. By enrolling immunocompromised individuals, children, and the elderly in clinical trials, researchers can gather critical data on the effectiveness and safety of new therapeutics. This approach not only improves the relevance of trial results but also helps in the development of tailored treatment protocols for different patient groups.
Segmental Insights
Treatment Insights
Based on Treatment, Smallpox Vaccine have emerged as the fastest growing segment in the Global Monkeypox Therapeutics Market in 2023. The smallpox vaccine, originally developed to combat the eradication of smallpox, has been found to offer cross-protection against Monkeypox. This cross-protection is due to the genetic and antigenic similarities between the smallpox and Monkeypox viruses, both of which belong to the Orthopoxvirus genus. The historical success of smallpox vaccination programs in reducing the incidence of smallpox has paved the way for its repurposing as a preventive measure for Monkeypox.
Recent outbreaks of Monkeypox, particularly in non-endemic regions, have revived interest in the smallpox vaccine. The vaccine’s ability to confer immunity against Monkeypox has led to its rapid adoption as a primary preventive tool. This has positioned the smallpox vaccine as a critical component of Monkeypox therapeutics, driving its rapid growth within the market.
Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have recognized the smallpox vaccine’s role in combating Monkeypox. Emergency use authorizations and accelerated approval processes for smallpox vaccines have facilitated their swift deployment in outbreak scenarios, further boosting market growth.
Governments and international health organizations are prioritizing vaccination campaigns to control Monkeypox outbreaks. These initiatives include stockpiling smallpox vaccines and implementing vaccination programs in high-risk areas. Such measures are driving the demand for vaccines and reinforcing their role in Monkeypox therapeutics.
The growing awareness of Monkeypox and the importance of preventive vaccination have led to increased investments in vaccine research and development. Pharmaceutical companies are focusing on enhancing vaccine formulations and improving storage and distribution capabilities, contributing to the segment’s growth.
End User Insights
Based on End User, Hospitals have emerged as the fastest growing segment in the Global Monkeypox Therapeutics Market during the forecast period. The rise in monkeypox cases has underscored the need for specialized medical care, which hospitals are uniquely equipped to provide. As the primary healthcare institutions for handling complex and severe cases, hospitals have become central to the management and treatment of monkeypox. The disease’s potential for severe symptoms and complications necessitates a level of care that hospitals, with their advanced diagnostic and therapeutic capabilities, are ideally positioned to offer.
Hospitals have increasingly become focal points for monkeypox treatment due to their comprehensive facilities, including isolation wards, intensive care units (ICUs), and access to a wide range of medical professionals. The ability to provide specialized care and advanced treatments has driven the demand for therapeutics within hospital settings, positioning them as a critical segment in the market.
The urgency of managing monkeypox outbreaks has further accelerated the growth of the hospital segment. Hospitals are at the forefront of response efforts, deploying therapeutics and managing patient care during outbreaks. This rapid response capability is crucial in controlling the spread of the disease and mitigating its impact on public health.
The need for hospitals to act quickly and efficiently during outbreaks has led to increased investment in therapeutic resources. Hospitals are enhancing their capacity to handle monkeypox cases by expanding their therapeutic inventories and establishing protocols for the swift administration of treatments. This proactive approach is a key driver of market growth within the hospital sector.
Hospitals are not only administering existing monkeypox therapeutics but are also pivotal in the development and testing of new treatments. Many hospitals participate in clinical trials for emerging therapeutics, providing valuable data and feedback that drives innovation in the market. This role as a testing ground for new therapies contributes to the growth of the hospital segment by increasing the demand for a wide range of therapeutics.
Additionally, hospitals often collaborate with pharmaceutical companies and research institutions to conduct studies and trials, further integrating new treatments into their care protocols. This collaboration facilitates the timely introduction of novel therapeutics to the market and reinforces the hospital segment's prominence.
Regional Insights
Based on Region, North America have emerged as the dominating region in the Global Monkeypox Therapeutics Market in 2023. North America boasts a highly developed healthcare infrastructure that is instrumental in the region's dominance in the Monkeypox Therapeutics Market. The United States and Canada have established, state-of-the-art healthcare systems with advanced medical facilities, extensive research institutions, and well-coordinated public health organizations. This infrastructure supports the rapid development, testing, and distribution of therapeutics. The presence of top-tier research institutions, such as the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), provides a robust foundation for conducting cutting-edge research and clinical trials, accelerating the availability of effective Monkeypox treatments.
North America’s dominance is also driven by its significant investment in research and development (R&D) within the pharmaceutical and biotechnology sectors. The region is home to numerous pharmaceutical giants and biotech firms that prioritize innovative therapeutic solutions for emerging and re-emerging diseases, including Monkeypox. Substantial R&D funding supports the development of new and improved treatments, ensuring that North America remains at the forefront of therapeutic advancements. Government initiatives, such as grants and subsidies for infectious disease research, further bolster the region's capacity to address Monkeypox and other health threats.
The robust regulatory framework in North America plays a crucial role in the region’s leadership in the Monkeypox Therapeutics Market. Agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada have established comprehensive regulatory processes that ensure the safety, efficacy, and quality of therapeutics. The streamlined approval processes for emergency use authorizations and accelerated pathways for therapeutic development enable quicker responses to outbreaks. This regulatory efficiency facilitates the rapid introduction of new Monkeypox treatments into the market, enhancing the region’s ability to address public health needs promptly.
Key Market Players
• Chimerix Inc.
• SIGA Technologies, Inc.
• Emergent BioSolutions Inc.
• Bavarian Nordic A/S
• Hetero Drugs Limited
• Mylan N.V.
• Piramal Enterprises Limited
• Olon S.p.A.
• Teva Pharmaceutical Industries Limited
• CIDIC Company Limited
Report Scope
In this report, the Global Monkeypox Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Monkeypox Therapeutics Market, By Treatment:
o Smallpox Vaccine
o Antivirals
o Vaccinia Immune Globulin (VIG)
• Monkeypox Therapeutics Market, By End User:
o Hospitals
o Specialty Clinics
o Ambulatory Surgical Centers
o Others
• Monkeypox Therapeutics Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Monkeypox Therapeutics Market.
Available Customizations:
Global Monkeypox Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).
ページTOPに戻る
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Global Monkeypox Therapeutics Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG))
4.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
4.2.3. By Region
4.2.4. By Company (2023)
4.3. Market Map
5. North America Monkeypox Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment
5.2.2. By End User
5.2.3. By Country
5.3. North America: Country Analysis
5.3.1. United States Monkeypox Therapeutics Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Treatment
5.3.1.2.2. By End User
5.3.2. Mexico Monkeypox Therapeutics Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Treatment
5.3.2.2.2. By End User
5.3.3. Canada Monkeypox Therapeutics Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Treatment
5.3.3.2.2. By End User
6. Europe Monkeypox Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment
6.2.2. By End User
6.2.3. By Country
6.3. Europe: Country Analysis
6.3.1. France Monkeypox Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment
6.3.1.2.2. By End User
6.3.2. Germany Monkeypox Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment
6.3.2.2.2. By End User
6.3.3. United Kingdom Monkeypox Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment
6.3.3.2.2. By End User
6.3.4. Italy Monkeypox Therapeutics Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Treatment
6.3.4.2.2. By End User
6.3.5. Spain Monkeypox Therapeutics Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Treatment
6.3.5.2.2. By End User
7. Asia-Pacific Monkeypox Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment
7.2.2. By End User
7.2.3. By Country
7.3. Asia-Pacific: Country Analysis
7.3.1. China Monkeypox Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment
7.3.1.2.2. By End User
7.3.2. India Monkeypox Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment
7.3.2.2.2. By End User
7.3.3. South Korea Monkeypox Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment
7.3.3.2.2. By End User
7.3.4. Japan Monkeypox Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment
7.3.4.2.2. By End User
7.3.5. Australia Monkeypox Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment
7.3.5.2.2. By End User
8. South America Monkeypox Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment
8.2.2. By End User
8.2.3. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Monkeypox Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment
8.3.1.2.2. By End User
8.3.2. Argentina Monkeypox Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment
8.3.2.2.2. By End User
8.3.3. Colombia Monkeypox Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment
8.3.3.2.2. By End User
9. Middle East and Africa Monkeypox Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment
9.2.2. By End User
9.2.3. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Monkeypox Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment
9.3.1.2.2. By End User
9.3.2. Saudi Arabia Monkeypox Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment
9.3.2.2.2. By End User
9.3.3. UAE Monkeypox Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment
9.3.3.2.2. By End User
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Merger & Acquisition (If Any)
11.2. Product Launches (If Any)
11.3. Recent Developments
12. Global Monkeypox Therapeutics Market: SWOT Analysis
13. Porters Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. Chimerix Inc.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. SIGA Technologies, Inc.
14.3. Emergent BioSolutions Inc.
14.4. Bavarian Nordic A/S
14.5. Hetero Drugs Limited
14.6. Mylan N.V.
14.7. Piramal Enterprises Limited
14.8. Olon S.p.A.
14.9. Teva Pharmaceutical Industries Limited
14.10. CIDIC Company Limited
15. Strategic Recommendations
16. About Us & Disclaimer
